Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Basso

Showing results (201-210 of 211) with videos related to

Pageof 22
Sort By:
Journal of Medicinal Chemistry|December 7, 2010
Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposureAngela D Kerekes, Sara J Esposite, Ronald J Doll, et al.
JACC. Heart Failure|January 14, 2020
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to SpironolactoneJordana B Cohen, Sarah J Schrauben, Lei Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|September 22, 2010
Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitorsDavid B Belanger, Michael J Williams, Patrick J Curran, et al.
Journal of the American College of Cardiology|March 21, 2020
Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection FractionJulio A Chirinos, Alena Orlenko, Lei Zhao, et al.
Hypertension (Dallas, Tex. : 1979)|September 28, 2020
Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart FailureJulio A Chirinos, Jordana B Cohen, Lei Zhao, et al.
Journal of Translational Medicine|October 18, 2008
Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cellsElizabeth A DiBlasio-Smith, Maya Arai, Elaine M Quinet, et al.
Journal of Lipid Research|March 26, 2009
LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouseElaine M Quinet, Michael D Basso, Anita R Halpern, et al.
Bioorganic & Medicinal Chemistry|October 2, 2020
Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidaseScott A Shaw, Benjamin P Vokits, Andrew K Dilger, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
PK/PD Disconnect Observed with a Reversible Endothelial Lipase InhibitorJon J Hangeland, Lynn M Abell, Leonard P Adam, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine CoreTao Yu, Jayaram R Tagat, Angela D Kerekes, et al.
Pageof 22

Showing results (201-210 of 211) with videos related to

Sort By:
Pageof 22
Journal of Medicinal Chemistry|December 7, 2010
Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposureAngela D Kerekes, Sara J Esposite, Ronald J Doll, et al.
JACC. Heart Failure|January 14, 2020
Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to SpironolactoneJordana B Cohen, Sarah J Schrauben, Lei Zhao, et al.
Bioorganic & Medicinal Chemistry Letters|September 22, 2010
Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitorsDavid B Belanger, Michael J Williams, Patrick J Curran, et al.
Journal of the American College of Cardiology|March 21, 2020
Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection FractionJulio A Chirinos, Alena Orlenko, Lei Zhao, et al.
Hypertension (Dallas, Tex. : 1979)|September 28, 2020
Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart FailureJulio A Chirinos, Jordana B Cohen, Lei Zhao, et al.
Journal of Translational Medicine|October 18, 2008
Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cellsElizabeth A DiBlasio-Smith, Maya Arai, Elaine M Quinet, et al.
Journal of Lipid Research|March 26, 2009
LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouseElaine M Quinet, Michael D Basso, Anita R Halpern, et al.
Bioorganic & Medicinal Chemistry|October 2, 2020
Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidaseScott A Shaw, Benjamin P Vokits, Andrew K Dilger, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
PK/PD Disconnect Observed with a Reversible Endothelial Lipase InhibitorJon J Hangeland, Lynn M Abell, Leonard P Adam, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine CoreTao Yu, Jayaram R Tagat, Angela D Kerekes, et al.
Pageof 22